Neurocrine Biosciences (NBIX) traded down -0.41 % during a 24 hours period ending at 11:55 PM Central Europe on Monday 26th. One Neurocrine Biosciences stock can currently be bought for about USD 145.87 on popular exchanges. Current supply of Neurocrine Biosciences stocks is 101.6 mn. Neurocrine Biosciences has a current market capitalization of USD 14.5 bn and approximately USD 147.5 mn worth of Neurocrine Biosciences was traded on exchanges in the last 24 hours. Since last month end, Neurocrine Biosciences has traded 2.71 % up. Simple moving average of last 200 days is at USD 147.09. The highest price of past 52 weeks was recorded at USD 186.12 on 07/30/2026. 52 weeks low was at USD 122.14 on 02/12/2026.
Here is how related stocks have performed in the past 24 hours:
Tpg Inc (TPG) traded down -3.31 % and now trades at USD 44.82. Tpg Inc has a market capitalisation of USD 17.2 bn. Current price/earnings ratio for Tpg Inc is 83.92.
Leidos (LDOS) traded up 1 % and now trades at USD 139.86. Leidos has a market capitalisation of USD 17.1 bn. Leidos has a current price to earnings ratio of 12.77.
Api (APG) traded up 1.68 % and now trades at USD 40.27. Current market capitalisation for Api is USD 17.1 bn.
Curtiss-wright (CW) traded down -1.97 % and now trades at USD 476.54. Curtiss-wright has a market capitalisation of USD 17.2 bn. Current price/earnings ratio for Curtiss-wright is 32.07.
Rivian Automotive (RIVN) traded down -1.91 % and now trades at USD 11.43. Current market capitalisation for Rivian Automotive is USD 17.1 bn.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a biotechnology company based in San Diego, California, United States. The company specializes in the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. Their therapeutic interventions are currently being developed for the treatment of conditions such as anxiety, depression, Alzheimer’s disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes. You can find more information about their work and achievements on their website, www.neurocrine.com , and they are listed on the Nasdaq stock exchange. Their Initial Public Offering (IPO) took place on May 23, 1996.
